Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Anderson

Podiatrist, Foot Surgery O'Fallon, IL Doctor of Podiatric Medicine

NPI 1790760494 CMS profile 1239739

717 Insight Ave, Suite 100, O'Fallon, IL 62269

Open in the dashboard

General payments

$13,359

93 records reported · program years 2019–2025

Research payments

$200,121

Paid to them · 25 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$556,241 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Christopher Anderson of O'Fallon, IL is reported in the CMS Open Payments database as having received $13,359 across 93 general payments and $200,121 in research payments paid to them. Separately, studies naming them as principal investigator received $556,241 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,045 28
2024 General $175 8
2023 General $2,132 19
2022 General $350 6
2021 General $447 9
2021 Research $56,262 3
2020 General $1,576 12
2020 Research $108,409 11
2019 General $6,635 11
2019 Research $35,450 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Anderson
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Christopher Anderson were reported at $2,045. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Christopher Anderson Podiatrist, Foot Surgery median Middle half National median
2019 $6,635 $167 $67–$484 $163
2020 $1,576 $114 $40–$323 $114
2021 $447 $171 $57–$502 $132
2022 $350 $196 $66–$556 $149
2023 $2,132 $187 $78–$466 $160
2024 $175 $190 $78–$557 $164
2025 $2,045 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Celularity, Inc. $6,339 4 payments
  2. Mylan Specialty L.P. $1,714 6 payments
  3. Endo USA, Inc. $1,549 8 payments
  4. Arthrex, Inc. $1,143 4 payments
  5. Stryker Corporation $682 14 payments
  6. Organogenesis Inc. $402 12 payments
  7. ETS Wound Care LLC $305 2 payments
  8. Treace Medical Concepts, Inc. $263 9 payments
  9. Elite Orthopedics, LLC $234 5 payments
  10. Zimmer Biomet Holdings, Inc. $119 2 payments
  11. Other $610 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,026 1 payment
  2. Food and Beverage $3,445 83 payments
  3. Travel and Lodging $3,019 8 payments
  4. Education $869 1 payment
Products named General payments · program years 2019–2025
  1. Biovance $313 3 payments
  2. UltraMist $267 1 payment
  3. Interfyl $267 1 payment
  4. MIRRAGEN ADVANCED WOUND MATRIX $233 1 payment
  5. LAPIPLASTY SYSTEM $164 5 payments
  6. ALLOWRAP $164 3 payments
  7. Puraply Antimicrobial $158 2 payments
  8. Affinity $149 4 payments
  9. VARIAX $139 1 payment
  10. Lapidus Plate $104 1 payment
  11. Other $1,646 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $164,671 14 payments
  2. Genentech, Inc. $35,450 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

230

Median for Podiatry: 160

Drug cost

$2,990

Median for Podiatry: $2,368

Branded share of claims

6.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluconazole Generic 15 $852
Ketoconazole Generic 32 $525
Diclofenac Sodium Generic 14 $500
Terbinafine Hcl Generic 43 $253
Gabapentin Generic 11 $217
Doxycycline Hyclate Generic 23 $208
Azithromycin Generic 32 $105
Amitriptyline Hcl Generic 13 $103
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $83
Mupirocin Generic 17 $81

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$107,201

Medicare's payments for the services billed

Medicare patients

206

Average age 76

Services billed

5,372

101 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 57%
Ischemic heart disease 44%
Chronic kidney disease 41%
Heart failure 31%
Atrial fibrillation 29%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record